EI
KYMR icon

EAM Investors’s Kymera Therapeutics KYMR Stock Holding History

EAM Investors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.53M Sell
42,341
-14,114
-25% -$1.12M 0.41% 117
2025
Q4 		$4.39M Sell
56,455
-1,130
-2% -$76.3K 0.49% 100
2025
Q3 		$3.21M Buy
+57,585
New +$2.6M 0.37% 135

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

EAM Investors's KYMR Position: Q1 2026 in Review

EAM Investors reduced its Kymera Therapeutics (KYMR) stake by 25% in Q1 2026, selling an estimated $1.12M and leaving 42,341 shares worth $3.53M. The position accounts for 0.41% of the portfolio, ranked #117.

EAM Investors first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.39M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • EAM Investors held 42,341 shares of Kymera Therapeutics worth $3.53M as of Q1 2026.
  • EAM Investors sold 14,114 Kymera Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Kymera Therapeutics made up 0.41% of EAM Investors's portfolio in Q1 2026, its #117 holding.
  • EAM Investors first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • EAM Investors's Kymera Therapeutics position peaked at $4.39M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.